{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:54:02Z","timestamp":1792547642933,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Few studies reported the characteristics of house dust mite (HDM) sublingual immunotherapy (SLIT) adverse events (AEs) during early phase treatment. The aim of this prospective study was mainly to explore the characteristics of AEs in allergic rhinitis (AR) patients during 6 months of HDM SLIT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 242 patients with AR were enrolled in this study. Telephone follow-up and administration were conducted in the every week of the first month, the third month, and the sixth month of SLIT treatment. Furthermore, the early efficacy, AEs, and compliance were analyzed in our study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 70.25% (170\/242) of the AR patients completed the study, while 29.75% (72\/242) of the AR patients failed to complete the whole 6 months of SLIT treatment process. On the whole, symptoms improved in 87.65% (149\/170) of patients including 34.12% (58\/170) well-controlled and 53.53% (91\/170) partially controlled. The correlation analysis results showed that the treatment effect was negatively correlated with the age (<jats:italic>r<\/jats:italic> = \u22120.1614, <jats:italic>P<\/jats:italic> = 0.0355). The AEs mainly occurred in the first month, comprised of local rashes, gastrointestinal reactions, and itching of mouth and tongue. Subgroup analysis in the first month showed the itching of mouth and tongue, gastrointestinal reactions, fatigue, and other AEs in \u226514 years old group (14\u201365 years old, <jats:italic>n<\/jats:italic> = 42) were significant differences when compared with that in the &amp;lt;14 years old group (4\u201313 years old, <jats:italic>n<\/jats:italic> = 128, all <jats:italic>P<\/jats:italic> &amp;lt; 0.05). In the study, the main reasons for terminated immunotherapy were drug inaccessibility, loss of follow-up and long course of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with AR who received HDM SLIT revealed an early efficacy after 6 months, with AEs mostly occurred in the first month.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1015032","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T05:40:27Z","timestamp":1669959627000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Characteristics of dust mite sublingual immunotherapy-associated adverse events in the early phase"],"prefix":"10.3389","volume":"9","author":[{"given":"Ming","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoxiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruonan","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"B1","first-page":"473","article-title":"Allergic rhinitis.","volume":"133","author":"Numminen","year":"2017","journal-title":"Duodecim."},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/ACI.0000000000000413","article-title":"Prevalence and clinical characteristics of local allergic rhinitis to house dust mites.","volume":"18","author":"Shin","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.13201\/j.issn.1001-1781.2018.17.018","article-title":"A brief introduction of local allergic rhinitis.","volume":"32","author":"Hu","year":"2018","journal-title":"Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi."},{"key":"B4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4168\/aair.2018.10.4.300","article-title":"Chinese society of allergy guidelines for diagnosis and treatment of allergic rhinitis.","volume":"10","author":"Cheng","year":"2018","journal-title":"Allergy Asthma Immunol Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.21037\/jtd.2017.10.112","article-title":"Chinese guideline on allergen immunotherapy for allergic rhinitis.","volume":"9","author":"Bao","year":"2017","journal-title":"J Thorac Dis."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2020.12.4.738","article-title":"Management practice of allergic rhinitis in china during the COVID-19 pandemic.","volume":"12","author":"Zhang","year":"2020","journal-title":"Allergy Asthma Immunol Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3760\/cma.j.cn115330-20210727-00487","article-title":"[Present status and future prospects of allergen immunotherapy in allergic rhinitis of China].","volume":"57","author":"Lou","year":"2022","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi."},{"key":"B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jaip.2016.09.017","article-title":"Current evidence on safety and practical considerations for administration of sublingual allergen immunotherapy (SLIT) in the United States.","volume":"5","author":"Epstein","year":"2017","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1111\/all.14417","article-title":"Acute systemic reactions to sublingual immunotherapy for house dust mite.","volume":"75","author":"Janssens","year":"2020","journal-title":"Allergy."},{"key":"B10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3760\/cma.j.cn115330-20211228-00828","article-title":"Chinese guideline for diagnosis and treatment of allergic rhinitis (2022, revision).","volume":"57","year":"2022","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.21037\/jtd.2019.12.37","article-title":"Chinese guideline on sublingual immunotherapy for allergic rhinitis and asthma.","volume":"11","author":"Li","year":"2019","journal-title":"J Thorac Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the world health organization, GA (2) LEN and AllerGen).","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ijporl.2013.05.032","article-title":"Suppression of TIM-1 predicates clinical efficacy of sublingual immunotherapy for allergic rhinitis in children.","volume":"77","author":"Lin","year":"2013","journal-title":"Int J Pediatr Otorhinolaryngol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/1939-4551-7-6","article-title":"Sublingual immunotherapy: world allergy organization position paper 2013 update.","volume":"7","author":"Canonica","year":"2014","journal-title":"World Allergy Organ J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/all.12874","article-title":"An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011.","volume":"71","author":"Wang","year":"2016","journal-title":"Allergy."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3760\/cma.j.issn.1673-0860.2016.01.004","article-title":"Chinese guidelines for diagnosis and treatment of allergic rhinitis.","volume":"51","year":"2016","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi."},{"key":"B17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.aller.2018.02.008","article-title":"Sublingual immunotherapy of house dust mite respiratory allergy in China.","volume":"47","author":"Cheng","year":"2019","journal-title":"Allergol Immunopathol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaci.2015.04.047","article-title":"International consensus on allergy immunotherapy.","volume":"136","author":"Jutel","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2500\/ajra.2014.28.4006","article-title":"Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis.","volume":"28","author":"Shao","year":"2014","journal-title":"Am J Rhinol Allergy."},{"key":"B20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/alr.21397","article-title":"Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases.","volume":"4","author":"Li","year":"2014","journal-title":"Int Forum Allergy Rhinol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/alr.21305","article-title":"Effects of sublingual immunotherapy for Dermatophagoides farinae on Th17 cells and CD4(+) CD25(+) regulatory T cells in peripheral blood of children with allergic asthma.","volume":"4","author":"Tian","year":"2014","journal-title":"Int Forum Allergy Rhinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.anai.2013.02.017","article-title":"Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012.","volume":"110","author":"Larenas-Linnemann","year":"2013","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40629-022-00218-5","article-title":"Sensitisation profile of Chinese allergic rhinitis patients and effectiveness of a joint allergy-ENT clinic.","author":"Hui","year":"2022","journal-title":"Allergo J Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2217\/imt-2021-0161","article-title":"Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study.","volume":"13","author":"Klein","year":"2021","journal-title":"Immunotherapy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/ijd.15977","article-title":"Sublingual immunotherapy with Dermatophagoides farinae drops for pediatric atopic dermatitis.","volume":"61","author":"Huang","year":"2022","journal-title":"Int J Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.jaip.2018.01.037","article-title":"Impact of adverse event solicitation on the safety profile of SQ house dust mite sublingual immunotherapy tablet.","volume":"6","author":"Nolte","year":"2018","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2217\/imt.15.88","article-title":"Rare adverse events due to house dust mite sublingual immunotherapy in pediatric practice: two case reports.","volume":"7","author":"Galip","year":"2015","journal-title":"Immunotherapy."},{"key":"B28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaip.2016.06.020","article-title":"Local side effects of sublingual and oral immunotherapy.","volume":"5","author":"Passalacqua","year":"2017","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/pai.12984","article-title":"Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: a randomized trial in a pediatric population.","volume":"30","author":"Okamoto","year":"2019","journal-title":"Pediatr Allergy Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.anai.2015.10.024","article-title":"Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.","volume":"116","author":"Maloney","year":"2016","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/all.14453","article-title":"COVID-19 pandemic: practical considerations on the organization of an allergy clinic\u2014An EAACI\/ARIA position paper.","volume":"76","author":"Pfaar","year":"2021","journal-title":"Allergy."},{"key":"B32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/alr.21909","article-title":"Nonadherence to sublingual immunotherapy in allergic rhinitis: a real-life analysis.","volume":"7","author":"Wang","year":"2017","journal-title":"Int Forum Allergy Rhinol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/alr.22553","article-title":"The effect of the standard length of the first prescription on the adherence to sublingual immunotherapy for patients with allergic rhinitis.","volume":"10","author":"Jin","year":"2020","journal-title":"Int Forum Allergy Rhinol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1015032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T05:40:33Z","timestamp":1669959633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1015032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":33,"alternative-id":["10.3389\/fmed.2022.1015032"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1015032","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"article-number":"1015032"}}